Company Description
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions.
The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.
It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays.
The company’s products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies.
In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services.
The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation.
It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents.
The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007.
Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
| Country | United States |
| Founded | 2007 |
| IPO Date | Dec 7, 2017 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 441 |
| CEO | Masoud Toloue |
Contact Details
Address: Building 1, 900 Middlesex Turnpike Billerica, Massachusetts 01821 United States | |
| Phone | 617 301 9400 |
| Website | quanterix.com |
Stock Details
| Ticker Symbol | QTRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001503274 |
| CUSIP Number | 74766Q101 |
| ISIN Number | US74766Q1013 |
| Employer ID | 20-8957988 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Masoud Toloue Ph.D. | President, Chief Executive Officer and Director |
| Dr. David R. Walt Ph.D. | Co-Founder, Chairman of Scientific Advisory Board and Independent Director |
| Vandana Sriram CPA | Chief Financial Officer and Treasurer |
| Dr. Michael Miller Ph.D. | Chief Operating Officer |
| Alexandra Phillips | Senior Vice President and Chief Information Officer |
| Naren Bhat | Senior Vice President of Corporate Development and Strategy |
| Erica Bell | Chief People Officer |
| Dr. Mark T. Roskey Ph.D. | Chief Science and Collaboration Officer |
| Darrin Crisitello M.B.A. | Senior Vice President and Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | SCHEDULE 13G | Filing |
| Nov 13, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 4, 2024 | 8-K/A | [Amend] Current report |
| Oct 3, 2024 | 8-K | Current Report |
| Aug 21, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jun 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |